To give an overview of promising novel agents under development for the prevention and reduction of gastrointestinal radiation injury.
INTRODUCTION
Radiotherapy plays a crucial role in the treatment of various cancers. Depending on the tumour site, it is delivered either before or after surgery or as a definitive treatment. Even though novel technical advances in treatment delivery have enabled more selective irradiation of the region of interest or tumour, normal tissue radiation toxicity remains the most important dose-limiting factor of radiotherapy. Injury to the gastrointestinal tract is often the most important cause of radiation-induced sideeffects in patients being treated for abdominal and pelvic tumours.
Symptoms of intestinal radiation injury may occur during and/or after treatment. Depending on the time of onset, intestinal radiation injury is divided into acute and chronic injuries. Acute radiation toxicity occurs during and shortly after the treatment period. It may affect the quality of life during treatment and may even require treatment interruption or alteration. The most important symptoms of acute gastrointestinal toxicity include diarrhoea, nausea, increased stool frequency, bleeding, abdominal and rectal/anal pain, decreased food uptake, and fluid and electrolyte loss. The severity of the symptoms may vary from mild discomfort to severely disabling and requiring hospital admission.
Chronic intestinal radiation injury is generally defined as injury present or occurring at least 3 months after treatment. The latency period of chronic radiation toxicity may be months up to years. Chronic gastrointestinal injury may reduce the quality of life in long-term cancer survivors. Again, the symptoms are various, including change in bowel habit, diarrhoea, faecal incontinence, pain, and intestinal blood loss.
In contrast to the earlier belief that acute and chronic injuries are two unrelated phenomena, it has now been recognized that part of the chronic effects is consequential to early toxicity.
Cancer patients could greatly benefit from pharmacological agents that are able to prevent or reduce gastrointestinal radiation injury. Unfortunately, to date, there are no effective pharmacological interventions to prevent the development of gastrointestinal radiation toxicity after abdominal or pelvic irradiation. There is some evidence from phase I and II trials that the thiol-containing compound, amifostine, may reduce rectum toxicity when administered either systemically or topically. However, in contrast to head and neck cancer, the usefulness of amifostine in radiotherapy for abdominal or pelvic cancer has not been confirmed in a phase III trial [1] [2] [3] [4] . Moreover, systemic amifostine treatment may cause severe side-effects [5] . Therefore, the use of amifostine is not widely implemented in clinical practice. Currently, intestinal radiation toxicity can only be managed symptomatically with analgesic, antiemetic agents, or drugs to reduce diarrhoea.
Hence, novel substances that can prevent or reduce intestinal radiation injury in cancer patients are urgently needed. During the last few years, it has become clear that these agents do not necessarily need to be radioprotectants, that is, agents administered before radiation exposure that protect the cell at the moment of exposure. Agents may also reduce radiation injury by targeting pathways more downstream in the pathogenesis of radiation injury [6 && ]. Administration of these substances may be started after radiation exposure. These agents are called radiation mitigators opposed to protectants. Recently, various novel target pathways to mitigate radiation injury have been discovered.
Remarkably, many of the recently indentified candidate agents to reduce radiation injury were not initially investigated to reduce radiation injury in cancer patients, but to reduce toxicity after radiation exposure in nonclinical situations. Lately, the sociopolitical climate has been supportive towards research programmes to develop novel radiation countermeasures for emergency situations such as nuclear accidents and terrorist attacks with radioactive material. This trend not only has provided novel opportunities and funds to develop interventions for nonclinical radiation exposure, but may also benefit cancer treatment. The newly discovered drug may develop as 'dual utility' drugs that can be used both as radiation countermeasure and in patients undergoing radiotherapy. The field of radiotherapy may therefore benefit from novel advances made in the development radiation countermeasures.
This review will discuss several promising novel drugs emerging from the laboratory that may be able to prevent or reduce intestinal radiation injury in cancer patients. The discussed agents appear to exert their effect by protection or stimulation of the intestinal epithelium, endothelium, or immune system.
SOMATOSTATIN ANALOGUES
Somatostatin analogues can ameliorate intestinal radiation injury by preventing postirradiation pancreatic enzyme-dependent intestinal autodigestion. Radiation exposure causes breakdown of the intestinal epithelial barrier because of a decrease in intestinal crypt/stem cell proliferation and inadequate cell supplies to compensate for continuous enterocyte loss. As a result, subepithelial tissues may be exposed to intraluminal pancreatic enzymes that subsequently aggravate the injury by initiating autodigestion of the intestine and the induction of inflammatory processes [7] . Strategies to reduce exogenous pancreatic secretion, like pharmacological inhibition with somatostatin analogues, have been shown to be effective in reducing intestinal radiation toxicity in animals.
Somatostatin analogues are already in clinical use for other indications like the treatment of neuroendocrine tumours and diarrhoeal syndromes [8] . Various animal studies have confirmed that
KEY POINTS
There is an urgent need for novel agents to prevent or reduce intestinal gastrointestinal radiation injury in patients being treated for abdominal and pelvic tumours.
Promising novel radioprophylactic and mitigating agents include the somatostatin analogue SOM230, growth factors, agents acting on the toll-like receptor 5 pathway, endothelial protectants, and the vitamin E analogue g-tocotrienol.
Before these newly discovered drugs can be clinically implemented, further research is needed to establish their safety and efficacy in reducing both acute and chronic gastrointestinal radiation injuries in patients.
treatment with the somatostatin analogue, octreotide, reduces intestinal radiation injury [9, 10] . Human studies investigating the effect of octreotide on postirradiation diarrhoea in patients being treated for rectal or anal cancer have shown mixed results [11, 12] . The fact that the studies only showed a modest or even no effect of octreotide might depend on the limited volume of small intestine, the site where somatostatin analogues are expected to exert their effect, in the radiation field.
The recently developed somatostatin analogue, SOM230 (pasireotide), may be more effective in reducing radiation injury than octreotide. It has a more favourable pharmacokinetic profile and broader receptor affinity. Studies in human subjects have shown that SOM230 is well tolerated [13] . Animal studies with SOM230 have shown that SOM230 reduces acute intestinal radiation injury by mechanisms depending on the inhibition of pancreatic enzyme secretion [14] . SOM230 was not only effective when started before radiation exposure, but also reduced radiation toxicity when started up to 48 h after exposure [15 & ]. At this moment, little information is known about the effect of SOM230 on tumour cell survival during radiotherapy. However, as SOM230 appears not to act as a cytoprotector, but to preserve the intestinal mucosa by reducing pancreatic enzyme secretion, it seems to be unlikely that SOM230 would protect tumour cells during radiotherapy. In fact, SOM230 may reduce the tumour growth by itself by inhibiting IGF-1 and VEGF secretion [16, 17] . Hence, SOM230 appears to be an attractive agent to reduce intestinal radiotoxicity during radiotherapy. SOM230 may be able to improve the therapeutic index of radiotherapy treatments in which the intestine, especially the small intestine, is in the radiation field. Phase I and II studies are needed to determine the safety and potential efficacy of SOM230 in abdominal and pelvic radiotherapy.
GROWTH FACTORS AND GROWTH FACTOR-LIKE AGENTS
The use of growth factors and growth factor-like agents to improve postirradiation intestinal epithelial recovery has been a popular research focus for several years. Various agents have been tested in this respect. Over the years, glucagon-like peptide 2 as well as keratinocyte and fibroblast growth factors has been shown to ameliorate postirradiation intestinal injury in various animal models [18] [19] [20] [21] [22] [23] . Moreover, recently, recombinant human epidermal growth factor as well as R-spondin 1, an intestinal stem cell growth factor, was shown to reduce apoptosis and improve recovery of the intestinal villi [24, 25] . These growth factors appear to exert their effect through inhibition of PUMA-dependent apoptosis and induction of Wnt-b-catenin regeneration [25, 26] .
Growth factor-like agents may be used to reduce radiation injury as well. For example, the growth factor-like lipid mediator lysophosphatidic acid (LPA) was shown to reduce postirradiation intestinal apoptosis through the LPA receptor 2 subtype [27] .
In the above-mentioned animal studies, the growth factors did not appear to affect the effects of radiation on tumours. However, further research is needed to confirm these results. If used to reduce acute radiation toxicity, it is almost inevitable to administer the drugs during the radiation course. Only growth factors that do not affect the radiationinduced tumour cell killing, tumour growth or other malignant tumour properties can be considered for clinical use.
AGENTS ACTING ON THE TOLL-LIKE RECEPTOR 5 PATHWAY
Toll-like receptors (TLRs) are an important component of the intestinal innate immunity. Activation of TLRs by commensal microflora is essential for the protection against intestinal injury and in the regulation of epithelial repair [28, 29] . Activation of TLRs reduces the sensitivity of enterocytes to radiation-induced apoptosis. The bacterial protein flagellin is a natural agonist of Toll-like receptor 5 (TLR5). Both flagellin and the less toxic synthetic flagellin derivate CBLB502 have been shown to be potent radioprotectors in both mice and nonhuman primates [30, 31] .
Pretreatment with TLR5 agonists prevents radiation-induced apoptosis of intestinal epithelial cells and subsequent injury. The c-jun N-terminal kinase (JNK) as well as nuclear factor kb (NF-kb) has been identified as pathways through which flagellin reduces radiation-induced enterocyte apoptosis [31,32 & 
].
A concern regarding the use of TLR5 receptor agonists is the possible induction of systemic inflammation. TLR5 receptor agonists can only be considered for clinical radioprotection if they do not induce effect-degrading toxicity [33] . In order to increase the specificity of the therapy, it might be necessary to use agents that act more downstream in the TLR5 receptor pathway than TRL5 receptor agonists. One of the candidate molecules is the mitogen-activated protein kinase phosphatase-7 (MKP-7) [32 & ]. TLR5 activation upregulates the transcription of MKP-7 and MKP-7 has already been shown to limit postirradiation injury.
Further research is needed to determine the safety and efficacy of the above-mentioned agents before they can be used clinically to prevent intestinal radiation injury.
ENDOTHELIAL PROTECTANTS
Strategies that reduce radiation-induced microvascular endothelial cell apoptosis or endothelial dysfunction may be able to prevent intestinal radiation injury [34] . Although under debate [35] [36] [37] , it is generally believed that postirradiation endothelial apoptosis contributes to intestinal stem cell dysfunction and mucosal injury [34] . The sphingolipid ceramide has been shown to play a crucial role in radiationinduced endothelial apoptosis. Radiation exposure can cause hydrolysis of cell membrane sphingomyelin by acid sphingomyelase which results in the formation of ceramide. Ceramide then initiates the apoptotic process via the mitochondrial system [38] . Bonnaud et al. showed that inhibition of postirradiation ceramide production promotes postirradiation endothelial survival and ameliorates intestinal injury in mice [39 & ]. Not only reducing endothelial apoptosis, but also improving postirradiation endothelial function with agents like 3-hydroxy-3-methyl-glutaryl-CoA (MHG-CoA), reductase inhibitors has been shown to reduce intestinal radiation injury in animal models [40, 41] .
Additional studies are needed before these strategies can be translated to the clinic.
g-TOCOTRIENOL
One of the other promising new agents to reduce intestinal radiation injury in mice is the vitamin E analogue g-tocotrienol. Vitamin E analogues or so-called tocols are powerful antioxidants with favourable toxicity profiles. Hence, they are interesting candidates for the development of radioprotectants.
Recently, it has become clear that there are remarkable differences in radioprotective potential among the various tocols. In the past, most studies on the effect of vitamin E on radiation toxicity were performed with a-tocopherol. a-Tocopherol is the most abundant isoform and the most widely used vitamin E supplement [42] [43] [44] [45] [46] [47] [48] . Several animal studies have now shown that other isoforms of vitamin E are more effective in ameliorating acute radiation toxicity [49] . Especially g-tocotrienol appears to be a powerful radioprotectant.
A single dose of g-tocotrienol administered before radiation exposure has been shown to decrease radiation injury in several organ systems, including the intestine, the hematopoietic system, and the vascular system [50, 51] .
With respect to the gastrointestinal syndrome, g-tocotrienol significantly improved intestinal crypt cell survival as well as the postirradiation recovery of the intestinal mucosal surface area. Moreover, considering the importance of vascular injury and the immune system in the development of intestinal radiation injury, the effects of g-tocotrienol on these systems may indirectly affect the intestinal system.
g-Tocotrienol may be efficient in reducing intestinal radiation injury because tocotrienols accumulate in the small intestine and colon to a higher level than tocopherols supplemented at the same concentration [52] . Other properties that may contribute to the powerful radioprotective effects of g-tocotrienol are its ability to concentrate in endothelial cells to levels that are 30-to 50-fold greater compared with a-tocopherol and to inhibit the enzyme MHG-CoA reductase [53, 54] .
In order to develop as a therapy to reduce radiation injury in patients undergoing radiotherapy, g-tocotrienol should not protect the tumour and should be safe to be used in humans. To date, little information is known about the effects of g-tocotrienol on tumour cells during radiotherapy. g-Tocotrienol may sensitize tumour cells to radiation exposure and chemotherapeutic agents [55] [56] [57] ; however, further studies are needed to confirm that g-tocotrienol does not protect tumour cells against radiation. With regard to the safety of g-tocotrienol in human beings, studies from other fields have shown that g-tocotrienol supplementation is well tolerated in humans [58, 59] .
CONCLUSION
During the last few years, several new agents have been shown to ameliorate intestinal radiation injury in animal models. Interestingly, some of these agents do not only prevent injury, but also mitigate injury when administration is started after radiation exposure.
Further research is needed to investigate the safety and efficacy of these newly discovered drugs in patients undergoing radiotherapy. Importantly, protective or mitigating agents can only be considered for clinical use if they are proven not to hamper the antitumour effect of the radiotherapy treatment.
With regard to the efficacy, it is crucial that both the effects on acute and late intestinal radiation injuries are assessed. Even though late injury may be consequential to acute toxicity, it is possible that certain agents are more effective against early toxicity than late injury and vice versa. In order to improve the quality of life of cancer patients, both agents that reduce acute and late injuries are needed.
Altogether, several promising radioprotectants and mitigating agents have emerged from the laboratory. These agents include SOM230, growth factors, agent acting on the TLR5 pathway, endothelial protectants, and g-tocotrienol. Now, the work should be continued and the clinical applicability and efficacy of these agents should be investigated.
